20/09/10
Alliance Pharma has a quite compelling business model and one that seems to have caught the attention of serial entrepreneur and investor Nigel Wray. Here boss John Dawson and his finance director Richard Wright update us on the progress the company has made in a rather busy six months.
08/09/10
The analyst sees higher sales in the second half, and highlighted that the highly cash generative, niche drug company upped its interim dividend by 143%.
27/05/10
The Cambridge Laboratories acquisition has been successfully integrated ahead of schedule, and the group looks forward to the rest of 2010 with confidence.
24/03/10
Sales rose 44 percent from a year earlier, driven by its rheumatology product Deltacortril, and the group is confident of further strong results in 2010.
08/02/10
The company is paying up to £17.8m for privately owned Cambridge Laboratories and expects the deal to be significantly earnings enhancing in the current full year.
